356 related articles for article (PubMed ID: 25860928)
21. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Sherriff J; Tamangani J; Senthil L; Cruickshank G; Spooner D; Jones B; Brookes C; Sanghera P
Br J Radiol; 2013 Feb; 86(1022):20120414. PubMed ID: 23385995
[TBL] [Abstract][Full Text] [Related]
22. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.
Rempel SA; Dudas S; Ge S; Gutiérrez JA
Clin Cancer Res; 2000 Jan; 6(1):102-11. PubMed ID: 10656438
[TBL] [Abstract][Full Text] [Related]
23. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.
Du R; Lu KV; Petritsch C; Liu P; Ganss R; Passegué E; Song H; Vandenberg S; Johnson RS; Werb Z; Bergers G
Cancer Cell; 2008 Mar; 13(3):206-20. PubMed ID: 18328425
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
25. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.
Goffart N; Kroonen J; Di Valentin E; Dedobbeleer M; Denne A; Martinive P; Rogister B
Neuro Oncol; 2015 Jan; 17(1):81-94. PubMed ID: 25085362
[TBL] [Abstract][Full Text] [Related]
26. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
27. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
[TBL] [Abstract][Full Text] [Related]
28. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
29. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract][Full Text] [Related]
30. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
32. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Ogura K; Mizowaki T; Arakawa Y; Ogura M; Sakanaka K; Miyamoto S; Hiraoka M
Radiat Oncol; 2013 Apr; 8():97. PubMed ID: 24499582
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
34. Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas.
Greenfield JP; Cobb WS; Lyden D
J Clin Invest; 2010 Mar; 120(3):663-7. PubMed ID: 20179347
[TBL] [Abstract][Full Text] [Related]
35. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
36. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
37. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
38. High-Mobility Group Box-1 Modulates the Expression of Inflammatory and Angiogenic Signaling Pathways in Diabetic Retina.
Abu El-Asrar AM; Mohammad G; Nawaz MI; Siddiquei MM
Curr Eye Res; 2015; 40(11):1141-52. PubMed ID: 25495026
[TBL] [Abstract][Full Text] [Related]
39. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
40. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Eisele G; Wick A; Eisele AC; Clément PM; Tonn J; Tabatabai G; Ochsenbein A; Schlegel U; Neyns B; Krex D; Simon M; Nikkhah G; Picard M; Stupp R; Wick W; Weller M
J Neurooncol; 2014 Mar; 117(1):141-5. PubMed ID: 24442484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
